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cell transplantation (HCT) arises from the newly engrafted
donor-derived hematopoietic progenitors and, at an early
time point, by homeostatic proliferation of immune effec-
tors transferred with the graft. The kinetics differ signiﬁ-
cantly between innate and adaptive immune populations
and the prompt recovery of monocytes and natural killer
(NK) cells contrast the delayed maturation of T and B cells,
which may not occur until the ﬁrst year after trans-
plantation. The restoration of functional immunity depends
on a multitude of treatment factors, particularly cellular
composition of graft, conditioning regimen, and type of
immunosuppressive therapy to prevent or treat graft-
versus-host (GVH) disease. Quantitative and functional
restoration of both immune system components is critical
to limit infectious risks and to alter relapse risk after
allogeneic HCT (Figure 1).
NK cells are innate lymphocytes capable of potent
cellular killing and cytokine production without prior an-
tigen encounter. Human NK cell activity is regulated by
predominant inhibitory signals from surface killer immu-
noglobulin receptor (KIR) complex or NKG2A receptors,
which interact with HLA class I molecules HLA-Bw4, HLA-
C1, HLA-C2 groups and HLA-E (NKG2A). Under normal
homeostatic conditions, a balance of activating and inhib-
itory signals tightly controls NK cell function. NK cell killing
can be triggered by missing HLA class I molecules on the
target cells that occurs with KIR-ligand mismatch in the
GVH direction, triggering activating receptors such as CD16,DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.11.681.
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and IL-18.
The contribution of NK cells to the graft-versus-tumor
response after HCT was ﬁrst suggested over a decade ago
by the Perugia group in HLA-haploidentical donors HCT us-
ing CD34-selected grafts. Ruggeri et al. reported impressive
protection from acute myeloid leukemia relapse for patients
who receive myeloablative transplants and T celledepleted
grafts with a KIR-ligand (HLA) mismatch in the GVH direc-
tion [1]. Others obtained opposite results in unrelated HCT
[2] without any ex vivo T cell depletion and 1 HLA mis-
matches in the GVH direction; however, discrepancies in
clinical results may well reﬂect heterogeneity in the trans-
plantation protocols, including disease type and status, use of
antieT cell globulin before transplantation, graft source,
degree of graft T cell depletion, occurrence of GVH disease,
and use of immunosuppressive drugs [3]. More recently,
donor KIR B/x genotype has been associated with relapse
protection in acute myeloid leukemia [4].
In this issue, Pical-Izard et al. present their work
detailing NK cell reconstitution and NK cell function in
patients treated with reduced-intensity reconditioning
(RIC) HCT using HLA-matched related and unrelated adult
donors for various hematologic malignancies [5]. They
studied NK cell phenotype, NK receptors expression, cyto-
toxicity, and cytokine and chemokine production in a
cohort of 45 patients who underwent uniform trans-
plantation using in vivo T cell depletion with antithymocyte
globulin (ATG) and post-transplantation cyclosporine. The
authors demonstrated impaired NK cell reconstitution after
a RIC/ATG regimen characterized by rapid accumulation of
immature CD56brightCD16 cells and a high level of inhibi-
tory NKG2A on CD56dim cells, which persisted for several
months. Maturation of NK cells was associated with loss of
NKG2A and acquisition of CD57, the marker of “memory NK
cells.” Not surprisingly, the study conﬁrmed the expansion
of the NKG2ANKG2CþCD57þ population after HCT with a
cytomegalovirus (CMV)-seropositive donor or after CMV
reactivation, as well as a skewed KIR proﬁle, in this subset
with higher frequency of KIR2DL2/L3/S2 expression. This
ﬁnding supports the hypothesis that CMV reactivation
generates a pool of long-lived NK cells with clonal expan-
sion potential [6]. It is interesting that other groups recently
Figure 1. Donor and transplantation-derived factors that affect NK cell reconstitution.
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conferred by NKG2CþCD57þ NK cells after CMV reactivation
is conﬁned to the RIC setting and does not occur after fully
myeloablative conditioning [7]. NK clonal expansion tends
to be ampliﬁed whenever T cellemediated control of CMV
infection is inefﬁcient or delayed, such as ATG use, as shown
by Pical-Izard et al. Although the intensity of conditioning
indeed may signiﬁcantly alter host antigen-presenting cells
and subsequent interactions with donor-derived immune
effectors, the potential implications of the CMV imprint on
the immune response to other infections and tumor control
with diverse conditioning regimen deserve further
investigation.
The important contribution of this paper is the correla-
tion of NK function with the clinical transplantation
outcomes. Although NK cells developed similarly from
HLA-matched related and unrelated donors, at rest they
exhibited partial cytotoxicity and chemokine (MIP-1beta)
secretion but poor cytokine production. However, largely
hypofunctional NK cells at 1 month after transplantation
were highly responsive to treatment with IL-12/IL-18,
resulting in TNF-alpha and IFN-gamma production and
increased degranulation against K562 targets. In this small
study of 26 patients, higher TNF-alpha production by NK
cells at 1 month correlated with overall survival and lower
relapse. Furthermore, NK cell killing conferred protection
from relapse in the ﬁrst year after HCT. These data
are noteworthy, as they indicate that better post-
transplantation outcomes after RIC HCT may be achieved
by improving NK cell reconstitution. Although antitumor
activity of immature donor-derived NK cells early after
transplantation may be limited at steady state, there is
opportunity for therapeutic intervention. NK cells may
respond to immune-enhancing strategies, such as tumor
targeting antibodies, novel bispeciﬁc killer engagers to
make NK cells antigen speciﬁc [8], IL-15 [9], and newimmunocytokine approaches that combine targeting and
activation.
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